Radiofrequency ablation for liver metastases in patients with gastric cancer as an alternative to hepatic resection
Menée en Corée du Sud à partir de données portant sur 18 patients présentant des métastases hépatiques isolées ayant pour origine un cancer de l'estomac et traitées entre 2000 et 2014, cette étude analyse, du point de vue de la survie, la possibilité d'une ablation des métastases par radiofréquence chez les patients ne pouvant bénéficier d'une résection hépatique
Background : The purpose of this retrospective study was to determine whether RFA could provide an alternative treatment modality for selected patients who are not candidates for hepatic resection. Methods : A total of 18 consecutive patients with liver metastases alone from gastric cancer treated with radiofrequency ablation (RFA, n = 11) or hepatic resection (HR, n = 7) at Seoul St. Mary’s Hospital, Korea, between January 2000 and September 2014, were enrolled. Results : The median OS and DFS in the RFA group were 40.5 ± 22.3 and 10.3 ± 1.07 months, respectively. There was no significant difference between the RFA and HR groups in terms of baseline characteristics except for performance status. Mean survival and DFS times of all patients were 60.1 ± 9.4 and 40.9 ± 10.2 months, respectively. Mean OS times in the HR and RFA groups were 67.5 ± 15.4 and 51.1 ± 9.8 months (P = 0.671), respectively, and the mean DFS time in the HR group (74.1 ± 14.2 months) was longer than that in the RFA group (26.9 ± 9.2 months), but the difference was not significant (P = 0.076). Conclusions : In patients who are not candidates for surgical treatment, RFA may be an alternative to HR.